As of 2025-07-16, the EV/EBITDA ratio of Aclaris Therapeutics Inc (ACRS) is -2.75. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Aclaris's latest enterprise value is 134.23 mil USD. Aclaris's TTM EBITDA according to its financial statements is -48.87 mil USD. Dividing these 2 quantities gives us the above Aclaris EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.2x - 10.2x | 8.0x |
| Forward P/E multiples | 11.2x - 17.2x | 14.6x |
| Fair Price | (4.76) - (4.31) | (4.84) |
| Upside | -412.9% - -383.2% | -418.6% |
| Date | EV/EBITDA |
| 2025-07-11 | -2.86 |
| 2025-07-10 | -2.90 |
| 2025-07-09 | -2.79 |
| 2025-07-08 | -2.59 |
| 2025-07-07 | -2.61 |
| 2025-07-03 | -2.57 |
| 2025-07-02 | -2.59 |
| 2025-07-01 | -2.50 |
| 2025-06-30 | -2.52 |
| 2025-06-27 | -2.64 |
| 2025-06-26 | -2.84 |
| 2025-06-25 | -2.99 |
| 2025-06-24 | -2.75 |
| 2025-06-23 | -2.46 |
| 2025-06-20 | -2.59 |
| 2025-06-18 | -2.52 |
| 2025-06-17 | -2.48 |
| 2025-06-16 | -2.57 |
| 2025-06-13 | -2.64 |
| 2025-06-12 | -2.77 |
| 2025-06-11 | -2.86 |
| 2025-06-10 | -2.72 |
| 2025-06-09 | -2.68 |
| 2025-06-06 | -2.77 |
| 2025-06-05 | -2.84 |
| 2025-06-04 | -2.95 |
| 2025-06-03 | -2.64 |
| 2025-06-02 | -2.57 |
| 2025-05-30 | -2.61 |
| 2025-05-29 | -2.61 |
| 2025-05-28 | -2.50 |
| 2025-05-27 | -2.19 |
| 2025-05-23 | -2.17 |
| 2025-05-22 | -2.17 |
| 2025-05-21 | -2.24 |
| 2025-05-20 | -2.37 |
| 2025-05-19 | -2.26 |
| 2025-05-16 | -2.28 |
| 2025-05-15 | -2.08 |
| 2025-05-14 | -1.99 |
| 2025-05-13 | -2.08 |
| 2025-05-12 | -2.15 |
| 2025-05-09 | -2.17 |
| 2025-05-08 | -2.28 |
| 2025-05-07 | -2.15 |
| 2025-05-06 | -2.21 |
| 2025-05-05 | -2.21 |
| 2025-05-02 | -2.57 |
| 2025-05-01 | -2.44 |
| 2025-04-30 | -2.44 |